



## Closure of Entitlement Offer

**5 November 2021 – Perth, Australia:** PharmAust Limited (ASX: PAA), is pleased to advise the closure on 2 November 2021 of the pro-rata non-renounceable rights issue of Entitlement Options via the Prospectus lodged with ASX and ASIC on 1 October 2021.

Entitlement Options were offered on the basis of 1 entitlement option for every 4 shares held at an issue price of 1 cent per entitlement option. The options have an exercise price of 20 cents and an expiry date of 31 October 2023.

Applications were received under the Offer for a total of 51,414,373 Entitlement Options for a total subscription amount received of \$514,143.73. Options will be allotted and holding statements dispatched to Optionholders as per the timetable.

Shortfall will be allocated and issued as per Section 4.5 of the Prospectus. The Shortfall will be issued on the same terms as being offered to Eligible Shareholders under the Prospectus. No related party will be issued with Shortfall without prior Shareholder approval.

This ASX release has been approved for release by Sam Wright on behalf of the Board of Directors.

### Enquiries:

Sam Wright  
Finance Director  
[sam@pharmaust.com](mailto:sam@pharmaust.com)